AstraZeneca faces questions over Covid-19 vaccine results after ‘manufacturing error’
‘Approval based on current data means people will be inoculated with a vaccine the true efficacy of which is unknown,’ one analyst says
26 November 2020 - 12:34
London — AstraZeneca and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.
While an announcement on Monday by AstraZeneca and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the UK partners have sparked worries about whether regulators would clear it. In a later statement, Oxford said a difference in manufacturing processes led to some participants being given a half dose instead of a full one...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.